Intervention
Surgery
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 102 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
60 shownNeoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Combined With Monoclonal Antibody in Locally Advanced NSCLCNCT07863999 · 2026-05-01
RECRUITINGTislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II StudyNCT07089199 · 2025-07-25
RECRUITINGPROMIS and Mobility Evaluation in Sarcoma PatientsNCT07227961 · 2025-07-01
RECRUITINGNeoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast CancerNCT06914440 · 2025-06-05
RECRUITINGCryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLCNCT06939127 · 2025-04-01
RECRUITINGToripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic CholangiocarcinomaNCT06721286 · 2024-11-12
RECRUITINGLong-Term Outcomes of Endoscopic-assisted vs Conventional Breast-conserving Surgery in Breast Cancer Patients After Neoadjuvant Therapy: a Randomized, Multicenter, Open Label, Non-inferiority TrialNCT06716073 · 2024-08-01
RECRUITINGEffect of Limb Length Ratio on Roux-en-Y Gastric Bypass Outcomes (CLIMB II Study)NCT06293703 · 2024-01-12
RECRUITINGTrial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer PatientsNCT06114108 · 2023-12-21
RECRUITINGMetastasis-directed Therapy for Oligometastases of Breast CancerNCT06135714 · 2023-11-08
RECRUITINGMONDRIAN: Multi-omics Integrative Modelling for Stereotactic Body Radiotherapy in Early-stage Non-small Cell Lung CancerNCT05974475 · 2023-09-11
RECRUITINGCOntinue the SaMe Systemic Therapy After Local Ablative Therapy for Oligo Progression in Metastatic Breast Cancer - the COSMO StudyNCT05301881 · 2023-04-17
RECRUITINGInduction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung CancerNCT05766800 · 2023-03-14
RECRUITINGTrial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLCNCT04875585 · 2021-05-12
RECRUITINGLocal Therapy for ER/PR-positive Oligometastatic Breast CancerNCT04698252 · 2021-04-01
RECRUITINGMetabolic Responses to Bariatric SurgeryNCT02024542 · 2011-02-01
RECRUITINGSpecimen and Data Study for Ovarian Cancer Early Detection and PreventionNCT00005095 · 2000-03-01
RECRUITINGPhase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)NCT07472478 · 2026-03-15
NOT_YET_RECRUITINGA Randomized Trial of Surgical Decision-Making Guided by TDTP-RECISTNCT07208526 · 2025-12-01
NOT_YET_RECRUITINGPrimary Tumor Resection Plus Osimertinib in Advanced EGFR-mutant Non-small Cell Lung CancerNCT07177092 · 2025-09-08
NOT_YET_RECRUITINGNeoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLCNCT06837948 · 2025-02-18
NOT_YET_RECRUITINGPreoperative Optimization of Diabetic PatientsNCT06589466 · 2025-01-22
ACTIVE_NOT_RECRUITINGInduction Therapy With Serplulimab Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung CancerNCT06591910 · 2024-09-20
NOT_YET_RECRUITINGPreoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung CancerNCT06357598 · 2024-01-18
UNKNOWNPerioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung CancerNCT06109402 · 2023-12-20
NOT_YET_RECRUITINGShort-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-negative Breast CancerNCT05843292 · 2023-07-01
NOT_YET_RECRUITINGNeoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 TrialNCT05891080 · 2023-07-01
NOT_YET_RECRUITINGEvaluation of Efficacy of Minimally Invasive Local Therapy for Lung Tumors and Its Impact on Breathing FunctionNCT07272356 · 2022-11-22
ACTIVE_NOT_RECRUITINGA Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast CancerNCT05415215 · 2022-07-05
COMPLETEDPrescision Medicine in Obstructive Sleep Apnea, Cardiovascular and Cerebrovascular Disease: AI Electrocardiogram Patch Does it AllNCT05566860 · 2022-06-23
UNKNOWNA Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor MalignanciesNCT05081609 · 2022-01-11
ACTIVE_NOT_RECRUITINGCognitive Impairment, Obesity, and the Effects of Bariatric SurgeryNCT05215886 · 2022-01-01
ENROLLING_BY_INVITATIONMortality of Cancer Surgery During SARS CoV2 PandemicNCT05240378 · 2021-10-29
COMPLETEDHigher Dose Preoperative taMOxifen in Premenopausal bREast Cancer PatientsNCT04997941 · 2021-10-21
ACTIVE_NOT_RECRUITINGSafety and Feasibility of Surgery After Conversion Therapy for Locally Advanced and Advanced NSCLCNCT04945928 · 2021-08-27
UNKNOWNNeoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLCNCT04943029 · 2021-08-20
UNKNOWNCHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung CancerNCT04062708 · 2021-03-10
ACTIVE_NOT_RECRUITINGStudy to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX TherapyNCT04770272 · 2021-03-01
TERMINATEDImpact on Quality of Life From Multi-modality Lung CancerNCT04540757 · 2020-11-25
UNKNOWNA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)NCT04436744 · 2020-09-04
COMPLETEDEfficacy and Safety of CRT, Durvalumab and Surgery for SSTNCT04465968 · 2020-09-01
NOT_YET_RECRUITINGPyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast CancerNCT04398914 · 2020-05-30
ACTIVE_NOT_RECRUITINGReal-time Intraoperative Breast Cancer Visualization for Margin AssessmentNCT02807597 · 2020-02-18
TERMINATEDA Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast CancerNCT04024462 · 2020-02-05
COMPLETEDThe Effectiveness and Safety of Resective Epilepsy Surgery for TRENCT04198181 · 2019-12-12
ACTIVE_NOT_RECRUITINGNeoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)NCT04040361 · 2019-11-30
UNKNOWNStudy of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast CancerNCT04109066 · 2019-11-18
COMPLETEDPyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast CancerNCT04066790 · 2019-09-09
TERMINATEDA Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast CancerNCT03916744 · 2019-07-26
COMPLETEDLong Term Outcomes of Bariatric Patients Treated With Surgery or EndoscopyNCT03705416 · 2019-03-30
ACTIVE_NOT_RECRUITINGMitochondria-targeted System Therapy Combined With Radiofrequency Ablation for Early-stage Non-small Cell Lung CancerNCT03840408 · 2019-01-31
UNKNOWNStudy of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)NCT03725059 · 2018-12-27
ACTIVE_NOT_RECRUITINGA Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung CancerNCT03800134 · 2018-12-06
ACTIVE_NOT_RECRUITINGCombination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast CancerNCT03982485 · 2018-10-16
ACTIVE_NOT_RECRUITINGNeoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast CancerNCT03595592 · 2018-09-07
ACTIVE_NOT_RECRUITINGA Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast CancerNCT03493854 · 2018-06-14
COMPLETEDTreatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (HIFU)NCT03742401 · 2018-06-11
TERMINATEDCombined Diagnosis of CT and Exosome in Early Lung CancerNCT03542253 · 2018-05-20
UNKNOWNA Study to Explore Clinical Characteristics and Prognoses of N2 Patients With Non-small Cell Lung CancerNCT03429192 · 2017-12-01
COMPLETEDStudy to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer PatientsNCT03272477 · 2017-10-05
COMPLETEDCommon conditions
Breast Cancer23Non-Small Cell Lung Cancer9Lung Cancer7Breast Cancer Invasive3Early Breast Cancer3Non Small Cell Lung Cancer3NSCLC3Obesity3Diabetes2Intrahepatic Cholangiocarcinoma (Icc)2Locally Advanced Non-Small Cell Lung Cancer2Morbid Obesity2Sarcoma2Stage IIIA Non-small Cell Lung Cancer2Triple-negative Breast Cancer22L+ Cervical Cancer1Activating EGFR Mutation1Advanced Cancer1Advanced Solid Tumor1Anatomic Stage IV Breast Cancer AJCC v81Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v81Anlotinib1Bariatric Surgery Candidate1Breast Fibroadenoma1Breast Neoplasms1
Leading sponsors
Hoffmann-La Roche
6
Shanghai Pulmonary Hospital, Shanghai, China
6
Shanghai Jiao Tong University School of Medicine
3
Swiss Cancer Institute
3
Alliance Foundation Trials, LLC.
2
Austrian Breast & Colorectal Cancer Study Group
2
Fondazione Michelangelo
2
H. Lee Moffitt Cancer Center and Research Institute
2
National Cancer Institute (NCI)
2
Palleos Healthcare GmbH
2
Tianjin Medical University Cancer Institute and Hospital
2
University of California, Davis
2
Washington University School of Medicine
2
Accuray Incorporated
1
AIO-Studien-gGmbH
1
Trial status mix
COMPLETED34
RECRUITING17
UNKNOWN16
ACTIVE_NOT_RECRUITING14
TERMINATED10
NOT_YET_RECRUITING9
ENROLLING_BY_INVITATION1
WITHDRAWN1
Phase mix
PHASE245
PHASE319
NA17
PHASE14
PHASE42
EARLY_PHASE11
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.